# Phase 3 Carcinoma, Non-Small-Cell Lung trials: 131 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 131 trials in phase 3 for Carcinoma, Non-Small-Cell Lung that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Carcinoma, Non-Small-Cell Lung trials: 131 rows for $6.55, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/carcinoma-non-small-cell-lung

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 131
- Recruiting or not yet: 131
- Read on: November 19, 2026

## Trials

The 25 newest of 131, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07943325 | Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer | Goethe University | Phase 3 | Not yet recruiting | Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943325) |
| November 2, 2026 | NCT07908745 | Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC | Ruijin Hospital | Phase 3 | Not yet recruiting | Non-Small-Cell Lung Cancer | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908745) |
| November 2, 2026 | NCT07908732 | Risk-Adapted Segmental Esophagus-Sparing Radiotherapy for Definitive Non-Small Cell Lung Cancer | Ruijin Hospital | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908732) |
| October 26, 2026 | NCT07896005 | A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Not yet recruiting | Non Small Cell Lung Cancer | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896005) |
| October 26, 2026 | NCT07895238 | A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC | West China Hospital | Phase 3 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 1,088 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895238) |
| October 16, 2026 | NCT07877584 | PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% | German Cancer Research Center | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877584) |
| September 16, 2026 | NCT07822542 | A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as... | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Carcinoma, Non-Small-Cell Lung | 448 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822542) |
| September 16, 2026 | NCT07821684 | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR... | AbbVie | Phase 3 | Not yet recruiting | Non-Squamous Non-Small Cell Lung Cancer | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07821684) |
| September 11, 2026 | NCT07816380 | A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic... | Guangzhou JOYO Pharma Co., Ltd | Phase 3 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816380) |
| September 9, 2026 | NCT07809256 | A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in... | EuroCityClinic LLC | Phase 3 | Recruiting | NSCLC (Non-small Cell Lung Cancer)R | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809256) |
| August 20, 2026 | NCT07777822 | Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous... | Revolution Medicines, Inc. | Phase 3 | Recruiting | NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung... | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777822) |
| August 10, 2026 | NCT07756645 | A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line... | AbbVie | Phase 3 | Recruiting | Non-Small Cell Lung Cancer | 940 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756645) |
| August 10, 2026 | NCT07754123 | Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Advanced or Metastatic NSCLC | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754123) |
| July 31, 2026 | NCT07738172 | Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer | National Taiwan University Hospital | Phase 3 | Recruiting | Lung Neoplasms, Non-Small Cell Lung Cancer | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738172) |
| July 2, 2026 | NCT07680790 | Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination... | Bristol-Myers Squibb | Phase 3 | Recruiting | Non-Small Cell Lung Cancer | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680790) |
| June 26, 2026 | NCT07672223 | A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 586 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672223) |
| June 25, 2026 | NCT07668752 | A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation | Genfleet Therapeutics (Shanghai) Inc. | Phase 3 | Recruiting | KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668752) |
| June 22, 2026 | NCT07660094 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) | Candel Therapeutics, Inc. | Phase 3 | Recruiting | Non-squamous, Non-Small Cell Lung Cancer | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660094) |
| June 11, 2026 | NCT07640789 | A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Non-small Cell Lung Cancer Stage III | 418 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07640789) |
| June 8, 2026 | NCT07633873 | SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07633873) |
| May 27, 2026 | NCT07608159 | Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. | Shanghai Pulmonary Hospital, Shanghai, China | Phase 3 | Not yet recruiting | Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy, Neoadjuvant Chemoimmunotherapy, Surgery | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07608159) |
| May 4, 2026 | NCT07566052 | A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation | Astellas Pharma Global Development, Inc. | Phase 3 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566052) |
| May 1, 2026 | NCT07560358 | Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560358) |
| April 28, 2026 | NCT07554339 | A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07554339) |
| April 21, 2026 | NCT07541170 | A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in... | Hoffmann-La Roche | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541170) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 9 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 5 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 4 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 4 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 3 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 3 |
| ETOP IBCSG Partners Foundation | 3 |
| National Cancer Institute (NCI) | 3 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 3 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 3 |
| Hunan Province Tumor Hospital | 2 |
| [Shanghai JMT-Bio Inc.](https://specstream.ai/data/clinical-trials/company/shanghai-jmt-bio-inc) | 2 |
| Instituto Nacional de Cancerologia de Mexico | 2 |
| Nuvation Bio Inc. | 2 |
| Guangzhou JOYO Pharma Co., Ltd | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| Ruijin Hospital | 2 |
| Beijing Pearl Biotechnology Limited Liability Company | 2 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 2 |
| [Allist Pharmaceuticals, Inc.](https://specstream.ai/data/clinical-trials/company/allist-pharmaceuticals-inc) | 2 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| Shanghai Pulmonary Hospital, Shanghai, China | 2 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 2 |
| Nuvalent Inc. | 1 |
| Tata Memorial Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 74 |
| United States | 50 |
| Italy | 40 |
| Spain | 40 |
| France | 39 |
| Canada | 38 |
| United Kingdom | 38 |
| Japan | 37 |
| Germany | 36 |
| Australia | 34 |
| Poland | 34 |
| South Korea | 34 |
| Brazil | 32 |
| Taiwan | 32 |
| Turkey (Türkiye) | 31 |
| Belgium | 28 |
| Netherlands | 27 |
| Argentina | 26 |
| Greece | 26 |
| Austria | 21 |
| Mexico | 21 |
| Romania | 21 |
| Chile | 20 |
| Hungary | 20 |
| Switzerland | 18 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Chicken restaurants in the United States](https://specstream.ai/data/businesses/chicken-restaurants/united-states)
- [Marble and granite professional companies in the United States](https://specstream.ai/data/businesses/marble-and-granite-professional-companies/united-states)
- [Water heater installers in the United States](https://specstream.ai/data/businesses/water-heater-installers/united-states)
- [Ethiopian restaurants in the United States](https://specstream.ai/data/businesses/ethiopian-restaurants/united-states)
- [Prenatal and perinatal care clinics in the United States](https://specstream.ai/data/businesses/prenatal-and-perinatal-care-clinics/united-states)
- [Barbecue restaurants in the United States](https://specstream.ai/data/businesses/barbecue-restaurants/united-states)
